Mezlocillin in doses of 1.0, 2.0, and 5.0 g and carbenicillin in doses of 2.0 g were given as bolus injections intravenously to 10 healthy volunteers. For mezlocillin, dose-dependent pharmacokinetics was detected. This is reflected by a more than proportional rise in serum concentrations and a decreased total body clearance as doses were increased. Per dose unit, the areas under serum concentration curves to infinity were 33.5 ,g.h/ml for the 1.0-g dose, 47.2 ,ug.h/ml for the 2.0-g dose, and 54.8 ,Lg.h/ml for the 5.0-g dose. The body clearance fell from 31.2 liters/h with the 1.0-g dose to 17.0 liters/h with the 5.0-g dose. This can be explained mainly by a marked depression of nonrenal clearance, which fell from 12.2 to 3.8 liters/h, compared with a parallel change in renal clearance from 19.0 to 13.2 liters/h. Contributing to the non-linearity may be biotransforination, evacuation via bile, or another process. With dose increments, rising amounts are recovered unchanged in the urine-61% after a 1.0-g dose compared with 69% after a 5.0-g dose. This clearly defines metabolism as a major factor of elimination. Carbenicillin, for which the first-order, two-compartment open model was applicable here as in previous studies, had a longer serum half-life than did mezlocillin. For the 2.0-g doses, the former had a half-life of 1.4 h, compared with 0.8 h for the latter (calculated as if the two-compartment model were fully valid). The relative area under the curve (see above) was 76.1 ug ih/ml after the 2.0-g dose. Chicago, Ill., Abstr. no. 346, 1976; K. Metzger, 15th ICAAC, Washington, D.C., Abstr. no. 332,1975 
Mezlocillin (BAY f 1353) is a new semisynthetic ureidopenicillin with an antibacterial spectrum which appears to be wider than that of ampicillin, carbenicillin, mecillinam, and several cephalosporins (2, 7, 10 (7, 10) . A level of 32 ,tg/ml has been used as upper limit for mezlocillin sensitivity (Bayer AG, personal communication (6, 8) .
Statistical analysis of significance followed the Wilcoxon nonparametric test (9) . RESULTS Serum concentrations. Mean serum concentrations and the variance are presented in Fig. 1 and Table 1 , respectively. There was relatively little variation among individuals. After a 2.0-g dose, the carbenicillin curve during the entire course was above that of mezlocillin.
There was a linear relationship between the doses of mezlocillin and the total area under the curves to infinity (Fig. 2) . However, the relative areas under the serum curves (F/total area under curve/dose) both the 2.0-g doses were significantly higher than that after the 1.0-g dose (P < 0.01). The fact that increased doses gave more than proportional rise in serum concentrations is apparent from Fig. 3 . The relative serum concentrations after doses of 1.0 and 5.0 g were significantly different for the entire observation period (P < 0.01). The same applies for 2.0-and 5.0-g doses after the first 45 min. The 2.0-g levels differed from the-1.0-g levels for the first 2 h.
Urine recovery. The mezlocillin recovered unchanged in the urine is recorded in Table 2 . Relatively more was excreted as the doses were increased, with means ranging from 61 to 69% of the total doses. Some 50 to 60% of the dose was excreted during the first 2 h. The mean half-life based on renal excretion was 0.7 h for the 1.0-g dose and 0.82 h for both the 2.0-and 5.0-g doses.
Pharmacokinetics. The hybrid intercepts and plasma disposition constants of the distribution phase (A and a, respectively) and the elimination phase (B and I), respectively) are shown in Table 3 .
The total body clearance (CIB), renal clearance (CIR), and metabolic clearance (ClM) (i.e., sum of nonrenal mechanisms) are shown in Table 4 . All decreased with increasing doses. The decrease in CIB was reflected by a pronounced reduction in the clearance due to nonrenal processes; the reduction in CIR was quite a bit less than than in ClM. ClB was lower for a 2.0-g dose of carbenicillin than for a 2.0-g dose of mezlocillin (P < 0.01). A very important finding was that CIB of mezlocillin decreased significantly with dose increments. There was a slight reduction in CIR, but the main reason was a marked reduction in clearance due to metabolism and possibly other extrarenal processes. CIR was 19.2 liters/h (317.0 ml/min) for the 1.0-g dose and 13.6 liters/h (219.0 ml/min) for the 5.0-g dose. Correspondingly, ClM fell from 12.2 to 3.8 liters/h. In view of the pattern of dose-dependent clearances and areas under the serum curves, we will limit the documentation mainly to dose-independent parameters.
The individual serum concentration curves do not deviate much from a bi-exponential course because drug disposition is not severely nonlinear and elimination is quite rapid. Hybrid intercepts and plasma disposition constants for the predominantly distributive phase (A and a) and of the predominatly eliminatory phase (B and fB) are shown in ized serum curves are not completely superimposable (Fig. 3) covery of unchanged drug in the urine indicates directly that a large portion of the compound is, indeed, metabolized. The higher percentage of unchanged drug also reflects the extent of the rate-limited biotransformation. As the dose is increased from 1.0 to 5.0 g, 8% escapes biotransformation. It is notable that after the 2.0-g doses carbenicillin, for which only the normal firstorder, two-compartment open model has been published, has a lower body clearance and consequently longer half-life than does mezlocillin.
The low urinary recovery could also reflect biliary excretion. In subjects with a healthy hepatobiliary system, about 25% of the 2.0-g mezlocillin dose has been recovered in bile (8 h The molecular weight is 580 for mezlocilhin and 422 for carbenicillin. It is notable that the ratio of the areas under the serum curves after 2.0-g doses approximately equals the inverse of the ratio of the molecular weights of the compounds, but this may be coincidental.
The pharmacokinetic properties of the two compounds are not in themselves indicative of a superior therapeutic potential for either compound. Lower mezlocillin concentrations might appear permissible by virtue of its higher antibacterial activity against many gram-negatives (e.g. Bacteroides spp., Pseudomonas aeruginosa, Proteus spp.). This is counterbalanced by the higher carbenicillin levels after equal doses. In view of the fact that the break point for mezlocillin sensitivity has been set at 32 ,ug/ml, it is noted that levels are maintained in serum only for some 2 h after the 5.0-g dose, for 0.85 h after the 2.0-g dose, and for about 15 min after the 1.0-g dose. Urine levels remain above that niveau for 6 to 8 hours regardless of dose. Because the drug has a fast distribution, dosage every 6 to 8 hours would be recommendable in most general infections. Dosage three times daily would probably suffice for urinary infections, at least if they are not complicated by tissue damage or reduced renal function. It would seem that 32 ,ug/ml is a realistic level for uncomplicated urinary tract infections. Strains with a minimal inhibitory concentration close to 32 ,ug/ml would seem to need 5.0-g doses, but this point requires clinical elaboration.
It is to be noted, however, that the carbenicillin concentrations and pharmacokinetic characteristics are mainly in accordance with previous publications (4, 5), although our mezlocillin levels are lower than those observed by others (however, they are not statistically different [3; Bayer AG, unpublished data]). In adults smaller than those entering this study and more similar to those studied elsewhere, we have noted concentrations similar to those found by others (unpublished data). The present mezlocillin levels are similar to those obtained for azlocillin (11) .
Comparing the same dose, the pharmacokinetic characteristics are in accordance with the findings of others (3). 
